Treace Medical Concepts, Inc. (NASDAQ:TMCI) Director James T. Treace Sells 10,000 Shares

average price of $21.00, for a total value of $210,000.00 The director of Treace Medical Concepts, Inc. sold 10,000 shares of the company's stock on Monday, May 1st. The stock was sold at an average price of $21.00 per share, for a total value of $210,000.

James T. Treace, the director of the company, sold 10,000 shares in a transaction on May 1, 2008. Stock was sold for $25.24 on average, a value of $252,400.00. After the sale was completed, the director owns 861.441 shares valued at $21,742,770.84. The SEC website

Treace Medical Concepts stock down 5.4 %

During trading hours, the stock price fell $1.40 to $24.63, a decrease of $1.40. Stock of the company traded at 215,807 shares compared to an average of 395,630. The company's debt-to equity ratio is 0.87. Its current ratio is 4.41, and its quick ratio is 3.77. The company's market cap is $1.51 billion. It has a price to earnings ratio of -31.9 and a beta value of -0.01. Treace Medical Concepts Inc.'s low for the past year was $12.48, and its high is $27.97. The company released its last quarterly earnings report on March 7th. The company's ($0.08) earnings-per-share (EPS) for quarter surpassed the consensus estimate ($0.13) by $0.05. Revenue for the company was $49.77 millions during the quarter. Treace Medical Concepts posted a negative return of equity of 54.51%, and a net margin of negative 30.19%. Analysts predict Treace Medical Concepts, Inc. to post a -0.8 EPS in the current year.

Wall Street analysts forecast growth

TMCI was the subject of a few recent research reports. Truist Financial began covering Treace Medical Concepts on Monday in a research note. They gave the company a rating of 'buy' and set a price target of $33.00. Stephens initiated coverage on Treace Medical Concepts shares in a research note on Monday, April 10. The company was given an 'equal-weight' rating with a price target of $26.00. Morgan Stanley raised their price target for Treace Medical Concepts shares from $28.00 up to $30.00 in a research note on March 8th. The stock was also given an 'overweight rating'. BTIG Research raised their price target for Treace Medical Concepts shares from $29.00 up to $32.00 in a report published on Monday, April 17. Four analysts have given the company a buy rating, while one analyst gave it a hold. According to MarketBeat data, the average rating for the stock is 'Moderate Buyer' with an average price target of $29.60.

Institutional Inflows & Outflows

TMCI has seen a number of hedge fund positions change recently. Altshuler Shaham Ltd purchased a new position of shares in Treace Medical Concepts valued at approximately $25,000 during the fourth quarter. UBS Group AG increased its holdings of Treace Medical Concepts from 79.1% to $25,000 in the third quarter. UBS Group AG owns now 1,442 shares worth $32,000, after adding 637 more shares. MCF Advisors LLC purchased a new Treace Medical Concepts position worth $45,000 in the third quarter. Van ECK Associates Corp purchased a new Treace Medical Concepts position in the fourth quarter for $52,000. TD Capital Management LLC also bought a position in Treace medical Concepts during the fourth quarter, worth $57,000. The company's shares are owned by institutional investors and hedge fund managers, who own 46.17 percent.

About Treace Medical Concepts

Get Rating

Treace Medical Concepts Inc is an orthopedic medical device manufacturer that designs, manufactures and markets medical devices to foot and ankle surgeons across the United States. It offers the Lapiplasty, a procedure that allows podiatric doctors to treat all three dimensions in the bunions. This provides patients with both a cosmetic and a medical improvement. offers a FREE daily email newsletter